Table 3.
Univariate analysis of patients with male genital EMPD and female genital EMPD, based on diagnosis of proximal or local neoplasms.
| MALE GENITAL EMPD (n=421) | FEMALE GENITAL EMPD (n=1,677) | |||||
|---|---|---|---|---|---|---|
| Characteristic | No proximal or local neoplasm (n=370) | Proximal or local neoplasm (n=51) | P-value | No proximal or local neoplasm (n=1,586) | Proximal or local neoplasm (n=91) | P-value |
| Age at diagnosis of EMPD (median, IQR) | 73.0 years (66.0–80.0) | 73.0 years (66.0–80.0) | 0.95 | 72.0 years (63.0–81.0) | 70.0 years (62.0–79.0) | 0.34 |
| Race | 0.08 | 0.56 | ||||
| White | 220 (59.5%) | 38 (74.5%) | 1,342 (84.6%) | 75 (82.4%) | ||
| Black | 0 (0.0%) | 0 (0.0%) | 11 (0.7%) | 1 (1.1%) | ||
| Asian, American Indian | 139 (37.6%) | 13 (25.5%) | 212 (13.4%) | 15 (16.5%) | ||
| Unknown | 11 (3.0%) | 0 (0.0%) | 21 (1.3%) | 0 (0.0%) | ||
| Marital status at diagnosis of EMPD | 0.89 | 0.36 | ||||
| Single (never married) | 29 (7.8%) | 3 (5.9%) | 143 (9.0%) | 8 (8.8%) | ||
| Married or domestic partner | 240 (64.9%) | 32 (62.8%) | 759 (47.9%) | 38 (41.8%) | ||
| Divorced, separated, or widowed | 42 (11.4%) | 6 (11.8%) | 522 (32.9%) | 38 (41.8%) | ||
| Unknown | 59 (16.0%) | 10 (19.6%) | 162 (10.2%) | 7 (7.7%) | ||
| Region of the United States a | 0.67 | 0.01 | ||||
| Northeast | 33 (8.9%) | 6 (11.8%) | 234 (14.8%) | 7 (7.7%) | ||
| Midwest | 37 (10.0%) | 4 (7.8%) | 184 (11.6%) | 20 (22.0%) | ||
| South | 29 (7.8%) | 6 (11.8%) | 218 (13.8%) | 11 (12.1%) | ||
| West | 271 (73.2%) | 35 (68.6%) | 950 (59.9%) | 53 (58.2%) | ||
| Year of EMPD diagnosis | 0.019 | 0.11 | ||||
| 1970–1989 | 24 (6.5%) | 8 (15.7%) | 170 (10.7%) | 8 (8.8%) | ||
| 1990–1999 | 67 (18.1%) | 12 (23.5%) | 252 (15.9%) | 23 (25.3%) | ||
| 2000–2009 | 158 (42.7%) | 23 (45.1%) | 678 (42.8%) | 38 (41.8%) | ||
| 2010–2014 | 121 (32.7%) | 8 (15.7%) | 486 (30.6%) | 22 (24.2%) | ||
| Surgery type for EMPD | 0.27 | 0.45 | ||||
| None | 58 (15.7%) | 8 (15.7%) | 204 (12.9%) | 12 (13.2%) | ||
| Local tumor destruction/excision | 135 (36.5%) | 15 (29.4%) | 230 (14.5%) | 12 (13.2%) | ||
| Partial removal of primary site | 75 (20.3%) | 7 (13.7%) | 567 (35.8%) | 25 (27.5%) | ||
| Total removal of primary site | 14 (3.8%) | 2 (3.9%) | 113 (7.1%) | 10 (11.0%) | ||
| Debulking or radical surgery | 5 (1.4%) | 0 (0.0%) | 93 (5.9%) | 5 (5.5%) | ||
| Surgery NOS or unknown | 83 (22.4%) | 19 (37.3%) | 379 (23.9%) | 27 (29.7%) | ||
| Vital status at end of follow-up period | 0.35 | 0.007 | ||||
| Alive | 207 (56.0%) | 25 (49.0%) | 957 (60.3%) | 42 (46.2%) | ||
| Dead | 163 (44.1%) | 26 (51.0%) | 629 (39.7%) | 49 (53.9%) | ||
a
Based on United States Census Bureau designations.
EMPD, extramammary Paget’s disease; IQR, interquartile range; NOS, not otherwise specified